Home › Research › Biomarkers
Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia
Sheikh-Bahaei N, Sajjadi SA, Pierce AL.. Current treatment options in neurology, 2017-11-14
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Purpose of review Alzheimer's disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. However, there are certain circumstances wherein detection of specific biomarkers of neurodegeneration or underlying AD pathology will impact the clinical diagnosis or treatment plan. We will review the currently available biomarkers for AD and frontotemporal dementia (FTD) and discuss their clinical importance. Recent findings With the advent of 18 F-labeled tracers that bind amyloid plaques, amyloid PET is now clinically available for the detection of amyloid pathology and to aid in a biomarker-supported diagnosis of AD or mild cognitive impairment (MCI) due to AD. It is not yet possible to test for the specific FTD pathologies (tau or TDP-43); however, a diagnosis of FTD may be "imaging supported" based upon specific MRI or FDG-PET findings. Cerebrospinal fluid measures of amyloid-beta, total-tau, and phospho-tau are clinically available and allow detection of both of the cardinal pathologies of AD: amyloid and tau pathology. Summary It is appropriate to pursue biomarker testing in cases of MCI and dementia when there remains diagnostic uncertainty and the result will impact diagnosis or treatment. Practically speaking, due to the rising prevalence of amyloid positivity with advancing age, measurement of biomarkers in cases of MCI and dementia is most helpful in early-onset patients, patients with atypical clinical presentations, or when considering referral for AD clinical trials.
What this study adds
Evidence grade: Low
This is a narrative review. This review states that amyloid PET and cerebrospinal fluid measures of amyloid-beta, total-tau and phospho-tau are clinically available to support a diagnosis of Alzheimer disease or mild cognitive impairment due to it. It advises using biomarker testing when there is diagnostic uncertainty and the result would affect diagnosis or treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sheikh-Bahaei, N., Sajjadi, S. A., & Pierce, A. L. (2017). Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia. Current treatment options in neurology. https://doi.org/10.1007/s11940-017-0484-z
Vancouver
Sheikh-Bahaei N, Sajjadi SA, Pierce AL. Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia. Current treatment options in neurology. 2017. doi:10.1007/s11940-017-0484-z. PMID: 29134465.
BibTeX
@article{sheikhbahaei2017-29134465,
author = {Sheikh-Bahaei, N. and Sajjadi, S. A. and Pierce, A. L.},
title = {{Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia}},
journal = {Current treatment options in neurology},
year = {2017},
doi = {10.1007/s11940-017-0484-z},
pmid = {29134465},
url = {https://doi.org/10.1007/s11940-017-0484-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Summary It is appropriate to pursue biomarker testing in cases of MCI and dementia when there remains diagnostic uncertainty and the result will impact diagnosis or treatment.
Why it matters
This review states that amyloid PET and cerebrospinal fluid measures of amyloid-beta, total-tau and phospho-tau are clinically available to support a diagnosis of Alzheimer disease or mild cognitive impairment due to it. It advises using biomarker testing when there is diagnostic uncertainty and the result would affect diagnosis or treatment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 34/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current treatment options in neurology) |
| Journal's citation record | 1 / 4 | Current Treatment Options in Neurology: journal h-index 77 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 26 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.4 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 2 / 6 | Cited 2.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Aimee L. Pierce: h-index 12 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29134465) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 34 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 40.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.